Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis
In Vivo · 2024
DOI: 10.21873/invivo.13761 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Joanna Stankiewicz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, By…. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Pediatric patients with primary refractory or relapsed B-cell non-Hodgkin lymphoma (B-NHL) have highly unfavorable prognosis. In this study, we retrospectively analyzed outcomes in pediatric B-NHL patients treated in a single center in Poland from 1995 to 2022, with emphasis on therapy results in patients with progression or relapse. PATIENTS AND METHODS: The primary objectives were a 5-year probability of overall survival (pOS) and a 5-year probability of event-free survival (pEFS). The secondary objectives involved the assessment of prognostic factors. RESULTS: A total of 76 children were eligible for the analysis. The 5-year pOS was 76.7%, and the 5-year pEFS was 72.9%. At diagnosis, elevated lactate dehydrogenase activity, the presence of B symptoms, bone marrow, skeletal or mediastinal involvement, and stage IV disease were associated with inferior outcomes. Nine children experienced progression and four relapse. The 5-year pOS for patients with progression was 38.1%. Two patients treated with hematopoietic stem cell transplantation (HSCT) as part of salvage therapy survived. However, only one out of seven patients who were treated without HSCT survived. The 5-year pOS was 0.0% in patients with relapsed disease. CONCLUSION: The most significant factor related to outcomes in pediatric B-NHL is therapy response, with a high mortality rate in children with refractory disease and relapse. There is no consensus on the salvage therapy approach; however, HSCT appears to be the optimal choice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland; joanna.konieczek@cm.umk.pl.
- Student Scientific Society, Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
- Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Zitieren
APA
Stankiewicz, J., Jabłońska, A., Treichel, P., Demidowicz, E., & Styczyński, J. (2024). Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis. In Vivo. https://doi.org/10.21873/invivo.13761
Vancouver
Stankiewicz J, Jabłońska A, Treichel P, Demidowicz E, Styczyński J. Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis. In Vivo. 2024. doi:10.21873/invivo.13761
BibTeX
@article{Stankiewicz2024,
author = {Stankiewicz, Joanna and Jabłońska, Anna and Treichel, Paweł and Demidowicz, Ewa and Styczyński, Jan},
title = {Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13761}
}
EUVIMED